SUPPLEMENT APPROVAL/
FULFILLMENT OF POSTMARKETING
REQUIREMENT

Viiv Healthcare Company
c/o GlaxoSmithKline
Attention: Stephen Hyatt, RAC
Project Manager, Global Regulatory Affairs
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709

Dear Mr. Hyatt

Please refer to your Supplemental New Drug Application (sNDA) dated and received May 31, 2017, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for TRIUMEQ (abacavir, dolutegravir, and lamivudine) tablet, 600mg/50mg/300mg.

This Prior Approval supplemental new drug application proposes the following changes:
- to expand the patient population to include treatment of HIV-1 infection in patients weighing at least 40 kg
- to add hepatotoxicity and risk of adverse reactions or loss of virologic response due to drug interactions information to WARNINGS AND PRECAUTIONS
- to update the ADVERSE REACTIONS and CLINICAL PHARMACOLOGY sections
- to revise the USE IN SPECIFIC POPULATIONS section based upon the Pregnancy and Lactation Labeling Rule (PLLAR) requirements.
- to add pediatric subsection, 14.2, in the CLINICAL STUDIES section
- to update PATIENT COUNSELING INFORMATION section
- to update Medication Guide to be consistent with the Prescribing Information

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

WAIVER OF HIGHLIGHTS SECTION

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information.
CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert and Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We note that you have fulfilled the pediatric study requirement for ages 12 to less than 18 years and weighing at least 40 kg for this application.

FULFILLMENT OF POSTMARKETING REQUIREMENT

We have received your submission dated May 31, 2017, containing the final report for the following postmarketing requirement listed in the August 22, 2014 approval letter.

2768-3 Evaluate the pharmacokinetics, safety and antiviral activity (efficacy) of abacavir/dolutegravir/lamivudine FDC tablets in HIV infected pediatric subjects 12 years to less than 18 years of age and weighing at least 40 kg. The safety and antiviral activity (efficacy) of abacavir/dolutegravir/lamivudine FDC tablets in
pediatric subjects should be evaluated for a minimum of 24 weeks. A clinical trial in children 12 to less than 18 years of age and weighing at least 40 kg may not be required if dosing recommendation for the FDC tablets can be supported by pediatric trials already conducted with the individual drug products.

We have reviewed your submission and conclude that the above requirement was fulfilled.

We remind you that there are postmarketing requirements listed in the August 22, 2014 approval letter that are still open.

**PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

OPDP Regulatory Project Manager  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion (OPDP)  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf).

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above, by fax to 301-847-8444, or electronically in eCTD format. For more information about submitting promotional materials in

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Linda Onaga, MPH, Regulatory Project Manager, at (301) 796-0759 or Christine Kim, PharmD, Regulatory Project Manager, at (301) 796-5964.

Sincerely,

{See appended electronic signature page}

Debra Birnkrant, MD
Director
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURES:
Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

DEBRA B BIRNKRANT
11/21/2017